ɬÀï·¬

Journal News

Flipping the switch

Courtney Chandler
Nov. 23, 2021

Eukaryotic cells must balance multiple factors before they can grow. The mechanistic target of rapamycin complex 1, or mTORC1, pathway senses and responds to various environmental cues, including nutrient availability, to control protein synthesis and cell growth.

The RagA–RagC GTPase heterodimer is required to activate mTORC1. Depending on amino acid availability, the RagA and RagC subunits will be oppositely loaded with either guanosine triphosphate or guanosine diphosphate, known as GTP and GDP. This variable nucleotide binding induces conformational changes in the heterodimer structure that promote the interaction or release of mTORC1.

When concentrations of amino acids in the cell are high, RagA is bound to GTP, and RagC is bound to GDP — this structural conformation facilitates mTORC1 interaction and activation of protein synthesis at the lysosomal surface. The reverse GTP/GDP loading leads to inhibition of mTORC1 and release from the lysosomal surface into the cytosol.

Until recently, researchers did not understand clearly how RagA and RagC maintain their oppositely nucleotide-loaded state to regulate mTORC1. In an in the Journal of Biological Chemistry, a team from the University of Massachusetts Chan Medical School describes the molecular mechanism behind this regulation and the consequences of disrupting this balance.

, an assistant professor at UMass and senior author on the article, described the RagA–RagC complex as a complicated light switch that controls mTORC1 — only when one switch is up and one switch is down will the mTORC1 lightbulb turn on.

“We were curious about the mechanism of regulation, because for us it’s like a black box and we didn’t understand how it worked,” Shen said.

Single-hydrogen-bond-890x376.jpg
Kuang Shen & Shawn Egri
A single hydrogen bond (in red in the box on the right) ensures the Rag GTPase complex can switch appropriately between the on and off states to regulate mTORC1 signaling and protein synthesis.

To peer into the black box, graduate student Shawn Egri used enzyme kinetics, structural biology and chemistry tools to probe the mechanism behind the regulation. Egri said he purified between 30 and 40 RagA–RagC mutants with individual amino acid differences and tested their activity one by one.

Eventually, the researchers identified mutants that eliminated normal RagA–RagC activity. They found that one interdomain hydrogen bond is all it takes to keep the switch in one position or the other and prevent it from spontaneously flipping between the two states.

“It was really amazing that just one hydrogen bond has this profound of an impact,” Shen said.

They next introduced mutants in which the interdomain hydrogen bond was broken (meaning the Rag GTPase cannot maintain its oppositely nucleotide-loaded state) into cells. They observed that with the interdomain hydrogen bond abolished, the GTPase subunits could not maintain their original nucleotide-loaded states in cells, leading to distorted responses to amino acid availability and altered mTORC1 interactions.

“It was surprising to us that our results (with purified proteins) translated so strongly in cells,” Egri said. “The phenotype was very clear even in wild-type cell background.”

In the future, Egri and Shen want to lock the complex in the on and off positions to see how that affects interactions with upstream regulators and downstream effectors of the mTORC1 pathway. This could help piece together a better idea of the signals and pathways that regulate the essential processes of protein synthesis and cell growth.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Courtney Chandler

Courtney Chandler is a biochemist and microbiologist in Baltimore, Md., and a careers columnist for ASBMB Today.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Melissa Moore to speak at ASBMB 2025
ASBMB Annual Meeting

Melissa Moore to speak at ASBMB 2025

April 2, 2025

Richard Silverman and Melissa Moore are the featured speakers at the ASBMB annual meeting to be held April 12-15 in Chicago.

 A new kind of stem cell is revolutionizing regenerative medicine
Feature

A new kind of stem cell is revolutionizing regenerative medicine

April 1, 2025

Induced pluripotent stem cells are paving the way for personalized treatments to diabetes, vision loss and more. However, scientists still face hurdles such as strict regulations, scalability, cell longevity and immune rejection.

Engineering the future with synthetic biology
ASBMB Annual Meeting

Engineering the future with synthetic biology

March 31, 2025

Learn about the ASBMB 2025 symposium on synthetic biology, featuring applications to better human and environmental health.

Scientists find bacterial ‘Achilles’ heel’ to combat antibiotic resistance
Webinar

Scientists find bacterial ‘Achilles’ heel’ to combat antibiotic resistance

March 28, 2025

Alejandro Vila, an ASBMB Breakthroughs speaker, discussed his work on metallo-β-lactamase enzymes and their dependence on zinc.

Host vs. pathogen and the molecular arms race
ASBMB Annual Meeting

Host vs. pathogen and the molecular arms race

March 28, 2025

Learn about the ASBMB 2025 symposium on host–pathogen interactions, to be held Sunday, April 13 at 1:50 p.m.

Richard Silverman to speak at ASBMB 2025
ASBMB Annual Meeting

Richard Silverman to speak at ASBMB 2025

March 27, 2025

Richard Silverman and Melissa Moore are the featured speakers at the ASBMB annual meeting to be held April 12-15 in Chicago.